Polyiclc
Advanced Malignancies
Seqker Biosciences, Inc.Phase 1/2Active
B
56/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 89/ 100
Competitive context
20 Active assets in the Advanced Malignancies cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ivuxolimab Pfizer | Phase 3 | BB |
Pelabresib Novartis Pharmaceuticals | Phase 3 | BB |
Brigatinib University Health Network, Toronto | Phase 3 | B |
Cmp 001 Pfizer | Phase 3 | B |
Lorlatanib Pfizer | Phase 3 | B |
View all 40 →
Same molecule, other indications
Polyiclc is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →